Anti-CD19 IgG Antibody

This purified recombinant monoclonal antibody is a human Anti-CD19 IgG which recognizes CD19 antigen. The variable regions for this antibody are based on an FDA-approved drug. This antibody has been tested for specific binding affinity to purified human CD19 protein (BPS Bioscience, #101015) in a colorimetric ELISA binding assay.

Product Specifications

Background

B-lymphocyte antigen CD19 (Cluster of Differentiation 19), also known as B-Lymphocyte Surface Antigen B4 and CVID3C, is a transmembrane protein expressed in follicular dendritic cells and all B lineage cells except plasma cells. CD19 plays two major roles in human B cells. It acts as an adaptor protein to recruit cytoplasmic signaling proteins to the membrane and it works within the CD19/CD21 complex to decrease the threshold for B cell receptor signaling pathways. Due to its presence on all B cells, it is a biomarker for B lymphocyte development and lymphoma diagnosis and can be utilized as a target for leukemia immunotherapies. CD19-targeted therapies based on T cells that express CD19-specific chimeric antigen receptors (CARs) have been utilized for their antitumor abilities in patients with CD19+ lymphoma and leukemia, such as Non-Hodgkins Lymphoma (NHL), CLL and ALL